Panel Discussion: Integrating Novel Combinations and Earlier Line Use in Diffuse Large B-Cell Lymphoma

Program Description

This in-depth discussion continues the review of novel drug classes in diffuse large B-cell lymphoma (DLBCL). Panelists will review strategies for the recognition and management of adverse effects associated with these novel agents, including evidence-based recommendations for supportive care and essential counseling points for patients. The discussion will cover emerging treatment trends, such as the potential shift of CAR T-cell therapies and bispecific antibodies into earlier lines of treatment and novel combination approaches, equipping pharmacists with the knowledge to navigate complex DLBCL management scenarios.

Target Audience: Oncology Pharmacist

Type of Activity: Application
Release date: September 30, 2025
Expiration date: September 30, 2026
Learner level: Foundational, Intermediate, Advanced
Time to complete activity: 0.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Explain the impact of emerging data and evolving strategies on diffuse large B-cell lymphoma (DLBCL) treatment
2. Analyze therapeutic sequencing strategies for immunotherapies in relapsed/refractory DLBCL, considering clinical evidence and real-world applications across diverse health care settings
3. Employ patient counseling strategies to optimize the safety and tolerability of DLBCL treatment and patient satisfaction